ChemicalBook
Chinese Japanese Germany

Telmisartan

Chemical Properties Mechanisms of Action Side Effects Patent
Telmisartan
Telmisartan
CAS No.
144701-48-4
Chemical Name:
Telmisartan
Synonyms
TU-199;PRITOR;BIBR 277;MICARDIS;Telmisaran;TIMISHATAN;BIBR 277SE;TELMISARTAN;TIMETAZIDINE;TelMisartan API
CBNumber:
CB4266172
Molecular Formula:
C33H30N4O2
Formula Weight:
514.63
MOL File:
144701-48-4.mol

Telmisartan Properties

Melting point:
261-263°C
Density 
1.16
RTECS 
DV2037500
storage temp. 
Hygroscopic, -20°C Freezer, Under Inert Atmosphere
solubility 
DMSO: >5 mg/mL at 60 °C
form 
solid
color 
white
Water Solubility 
insoluble
Merck 
14,9129
CAS DataBase Reference
144701-48-4(CAS DataBase Reference)

SAFETY

Hazard Codes  Xi
Risk Statements  36/37/38
Safety Statements  22-24/25-36-26
WGK Germany  2
Hazardous Substances Data 144701-48-4(Hazardous Substances Data)

Telmisartan price More Price(15)

Manufacturer Product number Product description CAS number Packaging Price Updated Buy
Sigma-Aldrich PHR1855 Telmisartan Pharmaceutical Secondary Standard; Certified Reference Material 144701-48-4 500mg $129 2017-11-08 Buy
Sigma-Aldrich 1643419 Telmisartan United States Pharmacopeia (USP) Reference Standard 144701-48-4 200mg $348.4 2017-11-08 Buy
TCI Chemical T2861 Telmisartan >98.0%(HPLC)(T) 144701-48-4 1g $84 2017-12-01 Buy
TCI Chemical T2861 Telmisartan >98.0%(HPLC)(T) 144701-48-4 5g $293 2017-12-01 Buy
Alfa Aesar J61441 Telmisartan, 99% 144701-48-4 1g $181 2017-11-08 Buy

Telmisartan Chemical Properties,Uses,Production

Chemical Properties

White or off-white crystalline powder, odorless and tasteless. Soluble in chloroform, slightly soluble in methanol, very slightly soluble in acetone, practically insoluble in water. Slightly soluble in 0.1mol/L hydrochloric acid, soluble in 0.1mol/L sodium hydroxide.
Absorption coefficient(E1%1cm):509~541

Mechanisms of Action

80mg of telmisartan for the human body will practically completely counter the high blood pressure caused by angiotension II. Effects will last for 24 and can still be detected within 48 hours. Blood pressure-lowering effects should gradually become apparent within 3 hours after the initial dose. If treatment is suddenly interrupted, blood pressure will return to the same level as before treatment in a matter of days, and there will be no rebound high blood pressure. In a clinical trial that compared two kinds of antihypertensive drugs, patients in the treatment group experienced lower rates of coughing than those in the group treated by angiotensin converting enzyme inhibitors.
Telmisartan has a half-life of 18~24 hours, and will take effect 1~4 hours after taken. Medicinal effects can last for as long as 35 hours, with a high (T/P) ratio and outstanding effects in controlling morning blood pressure. Thus, this medicine can effectively control blood pressure for 24 hours, and it meets the once-daily medicinal standard (40~80mg, qd).
Clinical effects and characteristics:
  • Pharmacokinetics show: Rapid effects (0.3h), long duration (35.4h), little effect on heart rate when lowering blood pressure.
  • Compared to Enalapril: Stronger antihypertensive effects than Enalapril; when both are used in combination with diuretics, Telmisartan still appears to be superior and results in a lower coughing rate.
  • Compared to Lisinopril: More apparent antihypertensive effects (for both systolic and diastolic blood pressure), coughing rate for Telmisartan (16%) is drastically lower than that of Lisinopril (60%).
  • Compared to Atenolol: Similar antihypertensive effects, lower rate of side effects (impotence and fatigue).
  • Compared to Amlodipine: The Telmisartan group experienced noticeably lower heart rates four hours after ingestion and from six a.m. to twelve p.m.
Overall, Telmisartan has the following characteristics in comparison with other antihypertensive medicine: specific receptor effects, noticeable hypertensive effects, good diuretic effects, improvement of myocardial stenosis, safe usage, good tolerance, and convenient daily dosage.

Side Effects

In the placebo control experiment, the incidence rate of negative events for the Telmisartan group (41.4%) was similar to that of the placebo group (43.9%). Negative events were unrelated to dosage, sex, age, or race.
The following lists negative reactions were accumulated via the 5788 hypertensive patients that were treated with Telmisartan in the clinical trial.
Negative effects are categorized by incident rate as:
Very common (>1/10); common (>1/100, <1/10=); uncommon (>1/1000, <1/100=); rare (>1/10000, <1/1000=); very rare (<1/100000=)
Bodily reaction: Common: Back pain (e.g. sciatica), chest pain, flu-like symptoms, infection symptoms (e.g. urinary tract infection including cystitis). Uncommon: sight abnormality, sweating.
Central and peripheral nervous system: Common: vertigo.
Digestive system: Common: stomach pain, diarrhea, indigestion, gastrointestinal disorders. Rare: dry mouth, bloating.
Muscle skeletal system: Common: joint pain, leg cramps or leg pain, muscle pain. Rare: Tenosensitis symptoms.
Nervous system: Rare: anxiety.
Respiratory system: Common: upper respiratory tract infection, including pharyngitis and rhinitis.
Skin and accessory system: Common: Skin abnormalities such as eczema.
Additionally, since Telmisartan entered the market, there have been individual cases of erythema, itching, syncope, insomnia, depression, stomach discomfort, vomiting, hypotension, bradycardia, tachycardia, dyspnea, eosinophilia, thrombocytopenia, weakness, and reduced work efficiency. Similar to other angiotensin II receptor blockers, very few cases have reported vascular edema, nettles, and other negative reactions.
The laboratory found: compared to the placebo, the Telmisartan group occasionally exhibited lowered hemoglobin or raised uric acid. Any increase in serum creatinine or liver enzymes in the Telmisartan group was similar or lower than that of the placebo group.

Patent

Telmisartan was originally formulated by the German pharmaceutical company Boehringer Ingelheim; it earned the German patent EP502,314 in 1991, was first approved to enter the American market in November 1998, and then entered German, Philippines, Australian, Belgium, British, and other markets.

Chemical Properties

White or off white crystalline powder

Uses

cardiotonic

Uses

Telmisartan is an angiotensin II receptor antagonist.

Uses

anti-cancer agent

Uses

Used alone or in combination with other classes of antihypertensives for the treatment of hypertension. Also used in the treatment of diabetic nephropathy in hypertensive patients with type 2 diabetes mellitus, as well as the treatment of congestive heart

Definition

ChEBI: A member of the class of benzimidazoles used widely in the treatment of hypertension.

Telmisartan Preparation Products And Raw materials

Raw materials

Preparation Products


Telmisartan Suppliers

Global( 404)Suppliers
Supplier Tel Fax Email Country ProdList Advantage
Jiangsu Zhongbang Pharmaceutical Co., Ltd.
025-87151996
025-87151996 zbsales@chinaredsun.com CHINA 32 55
Capot Chemical Co.,Ltd.
+86 (0)571-855 867 18
+86 (0)571-858 647 95 sales@capotchem.com China 19953 60
Henan Tianfu Chemical Co.,Ltd.
0371-55170693
0371-55170693 info@tianfuchem.com CHINA 10013 55
Mainchem Co., Ltd.
0592-6210733
0592-6210733 sales@mainchem.com CHINA 1948 55
Shenzhen Sendi Biotechnology Co.Ltd.
0755-23311925 18102838259
0755-23311925 Abel@chembj.com CHINA 3229 55
Hubei Xinyuanshun Pharmaceutical Chemical Co., Ltd. 027-50664929 / 13971561712
027-50664927 / QQ: 3452835437 hubxys2001@163.com China 2014 55
Zhuhai Beri Medical Technology Co., Ltd +86(0756)8699 456
+86(0756)8699 456 sales@zhberi.com China 143 58
Guangzhou Kafen Biotech Co.,Ltd 020-31121484 18027468163 QQ:2355327168
020-31121510 gy@yccreate.com China 5000 55
Jiangsu United-value International Trading Co., Ltd. 0519-89885611 89885616 15312500313
+86(519)89885615 luke.li@uvcs.cn.com China 584 58
J & K SCIENTIFIC LTD. 400-666-7788 +86-10-82848833
+86-10-82849933 jkinfo@jkchemical.com;market6@jkchemical.com China 96820 76

144701-48-4(Telmisartan)Related Search:


  • TU-199
  • TELMISARTAN
  • PRITOR
  • MICARDIS
  • BIBR 277
  • 144701-48-4
  • 4'[(1,4'-DIMETHYL-2'-PROPYL[2,6'-BI-1H-BENZIMIDAZOL]-1'-YL)METHYL][1,1'-BIPHENYL]-2-CARBOXYLIC ACID
  • 4'-[(1,4'-DIMETHYL-2'-PROPYL[2,6'-BI-H-BENZIMIDAZOL]-1'-YL)METHYL][1,1'-BIPHENYL]-2-CARBOXYLIC ACID
  • 3-methoxy-8-[(4-methoxy-3,5-dimethyl-pyridin-2-yl)methyl sulfinyl]-2,7,9-triazabicyclo[4.3.0]nona-2,4,8,10-tetraene
  • [1,1'-Biphenyl]-2-carboxylic acid, 4'-[(1,4'-dimethyl-2'-propyl[2,6'-bi-1H-benzimidazol]-1'-yl)methyl]-
  • 4'-[[1,4'-Dimethyl-2'-propyl[2,6'-bi-1H-benzimidazol]-1'-yl]-methyl]-1,1'-biphenyl-2carboxylic acid,dimethylethyl ester
  • Telmisaran
  • Telmisartan99.5%
  • TelmisartanC33H30N402
  • C16H18N4O3S
  • C33H30N4O2
  • Micardis, Pritor, 4[(1,4Dimethyl-2propyl[2,6bi-H-benzimidazol]-1yl)methyl][1,1biphenyl]-2-carboxylic Acid,
  • TIMETAZIDINE
  • TIMISHATAN
  • 4′-((2-n-Propyl-4-methyl-6-(1-methylbenzimidazol-2-yl)-benzimidazol-1-yl)methyl)biphenyl-2-carbonsure
  • 1447014-48-4
  • Pharmaceutical material and intermeidates
  • Active Pharmaceutical Ingredients
  • C37H38N4O2
  • 4'-[{1,4'-Dimethyl-2'-Propyl[2,6'-Bi-1H-Benzimiaszol]-1'yl}-Methyl}-1,1'-Biphenyl-2-Caroxylic Acid
  • INTERMEDIATESOF
  • Antihypertensive
  • 4'-[{1,4'-Dimethyl-2'-Propyl[2,6'-Bi-1H-Benzimiaszol]-1'yl}-Methyl}-1,1'-Biphenyl-2-Caroxylic Acid Dimethyl Ethyl Ester
  • Imidazoles
  • (intermediates of telmisartan)
  • 4''-(1,7''-DIMETHYL-2''-PROPYL-1H-[2,5'']BIBENZOIMIDAZOLYL-3''-YLMETHYL)-BIPHENYL-2-CARBOXYLIC ACID
  • 4-chloromethyl-5-methyl-1,3-dioxol-2-tone
  • Telmisartan
  • 4'-(1,7'-Dimethyl-2'-propyl-1H-
  • Hypertension
  • Intermediates & Fine Chemicals
  • Pharmaceuticals
  • API's
  • BIBR 277, 4μ[(1,4μ-Dimethyl-2μ-propyl[2,6μ-bi-1H-benzimidazol]-1μ-yl)methyl][1,1μ-biphenyl]-2-carboxylic acid
  • C20H24N2O5SD4
  • C33H27N4O2D3
  • 4'-[[4-Methyl-6-(1-methyl-2-benzimidazolyl)-2-propyl-1-benzimidazolyl]methyl]-2-biphenylcarboxylic acid
  • Telmisartan,4′[(1,4′-Dimethyl-2′-propyl[2,6′-bi-1H-benzimidazol]-1′-yl)methyl][1,1′-biphenyl]-2-carboxylic acid, BIBR 277
  • 4'-[[1,4'-Dimethyl-2
  • Other Products
  • Telmisartan (150 mg)
  • 2-(4-{[4-Methyl-6-(1-Methyl-1H-1,3-benzodiazol-2-yl)-2-propyl-1H-1,3-benzodiazol-1-yl]Methyl}phenyl)benzoic acid
  • TelMisartan (Micardis)
  • BIBR 277SE
  • TelMisartan API
  • Hypertension.
  • 4'-[[4-Methyl-6-(1-methyl-1H-benzimidazol-2-yl)-2-propyl-1H-benzimidazol-1-yl]methyl]biphenyl-2-carboxylic Acid
  • 4'-((1,7'-DiMethyl-2'-propyl-1H,3'H-[2,5'-bibenzo[d]iMidazol]-3'-yl)Methyl)-[1,1'-biphenyl]-2-carboxylic acid
  • 4'-((1,7'-Dimethyl-2'-propyl-1H,3'H-[2,5'-bibenzo[d]imidazol]-3'-yl)methyl)-[1,1'-biphenyl]-2-car
  • CARADRIN
  • Telmisartan Synonyms 4'[(1,4'-Dimethyl-2'-propyl[2,6'-bi-1H-benzimidazol]-1'-yl)methyl][1,1'-biphenyl]-2-carboxylic acid
  • (1,1'-Biphenyl)-2-carboxylic acid, 4'-((1,4'-dimethyl-2'-propyl(2,6'-bi-1H-b
  • 2-[4-[[4-methyl-6-(1-methyl-2-benzimidazolyl)-2-propyl-1-benzimidazolyl]methyl]phenyl]benzoic acid
Copyright 2017 © ChemicalBook. All rights reserved